Sun Pharmaceutical Industries Ltd. (NSE: SUNPHARMA) has remained one of the most stable pharma companies in FY25. With defensive characteristics and a diversified global footprint, the stock has offered investors both capital appreciation and dividend returns.
On April 30, 2025, Sun Pharma ended the trading day at ₹1,835.42, recording a 1.41% gain even as the BSE Sensex showed little movement.
Over the past 12 months, the stock has surged over 22%, outperforming key indices like Nifty Pharma and the broader Nifty 50. Here, we will see what the chart says about Sun Pharma stock.
Earnings Update: FY25 Q3 Financials
Sun Pharma’s financial results for the latter half of FY25 show its robust operational performance and strategic focus.
Q3 FY25 Highlights
- Revenue: ₹13,436 crore, marking a 10.5% year-on-year (YoY) growth, driven by strong domestic and emerging market sales.
- Net Profit: It stood at ₹2,903 crore, marking a 15% year-on-year rise and exceeding market projections.
- EBITDA: ₹4,009 crore, with margins improving to 29.3%, up 150 basis points YoY.
- India Formulations Sales: ₹4,300 crore, accounting for 32% of total sales, reflecting a 13.8% YoY growth.
- Research and Development Spending: It reached ₹845 crore, accounting for 6.3% of revenue, underscoring the company’s ongoing commitment to innovation.
For Q4, figures are pending, analysts anticipate continued company growth supported by the specialty portfolio and steady performance in chronic therapies.
However, sequential revenue may experience a slight dip due to seasonality and emerging market dynamics.
What Does the Chart Say?
On TradingView, the Sun Pharma share price, which is around Rs. 1670+ at present, has exhibited a steady upward trajectory over the past months, with a 5.36% increase in the last one month.
The 52-week range spans from ₹1,377.20 to ₹1,960.20, indicating strong investor confidence.
The stock’s high market valuation is demonstrated by its current price-to-book (P/B) ratio of 6.37 and price-to-earnings (P/E) ratio of 38.42.
The relative strength index (RSI) currently hovers around 54.727, suggesting the stock is neither overbought nor oversold. The median 12-month target for Sun Pharma shares stands at ₹2,017, with a bullish ceiling estimate of ₹2,450 and a floor of ₹1,500.
A common bullish thesis is Sun Pharma’s differentiated portfolio, low net debt, and ability to weather regulatory risks through a diversified base across the US, India, and emerging markets.
Shareholding Breakdown (as of March 31, 2025)
The shareholding pattern of Sun Pharma is divided between promoters, the public, FIIs, and DIIs in the following ratio:
- Promoters: 48% (0.69% pledged).
- FII: 04%, a marginal increase from 18.01% in Dec 2024.
- DII: 46% (12.21 in mutual funds), slightly lower than the previous quarter.
- Public & Others: 09%.
The increase in FII holding signals global optimism toward Sun Pharma’s long-term fundamentals.
Dividend & Valuation Metrics
- Total Dividend Payout (FY25): ₹10 per share, implying a dividend yield of 0.75% at the current market price. As a result, the business announced a 1050% dividend on each share’s face value of Rs 1.
- EPS (Trailing Twelve Months): ₹47.69.
- Market Cap: ₹4,39,630 crore.
While the dividend yield may appear modest, Sun Pharma’s consistent payout policy reflects its cash-rich position and stable earnings visibility.
The stock trades at a premium, but analysts attribute this to its strong pipeline of specialty drugs and expanding presence in regulated markets.
The Bottom Line
Sun Pharma continues to show strength in both its fundamentals and stock performance. From rising institutional interest to consistent earnings delivery, the company remains well-positioned in India’s defensive pharma sector.
Investors looking for a combination of stable returns, modest dividends, and potential upside from global expansion can consider tracking this stock closely.